Trial Profile
Phase1 Study of Recombinant Stem Cells That Repair Lung Injury in H7N9 Infected Patients
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 01 Feb 2019
Price :
$35
*
At a glance
- Drugs Menstrual blood-derived mesenchymal stem cells (Primary)
- Indications Acute lung injury
- Focus Therapeutic Use
- Sponsors S-Evans Biosciences
- 20 May 2015 New trial record